Drs. Bessette and Kinch reply

REFERENCES

1. 1.↵
   1. Bessette L,
   2. Mysler E,
   3. Kinch CD, et al.

   Impact of tofacitinib on components of the ACR response criteria: post hoc analysis of phase III and phase IIIb/IV trials. J Rheumatol 2022;49:566-76.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Tchetina EV.

   Baseline gene expression analysis in the peripheral blood of patients with rheumatoid arthritis as an important supplement to a standard composite measure. J Rheumatol 2023;50:577–8.

   OpenUrlFREE Full Text
3. 3.↵
   1. Tchetina EV,
   2. Satybaldyev AM,
   3. Markova GA,
   4. Samarkina EY,
   5. Lila AM.

   Putative association between low baseline gene expression in the peripheral blood and clinical remission in rheumatoid arthritis patients treated with tofacitinib. Life 2021;11:1385.

   OpenUrl
4. 4.↵
   1. Weyand CM,
   2. Wu B,
   3. Goronzy JJ.

   The metabolic signature of T cells in rheumatoid arthritis. Curr Opin Rheumatol 2020;32:159-67.

   OpenUrl
5. 5.↵
   1. Criswell LA,
   2. Lum RF,
   3. Turner KN, et al.

   The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum 2004;50:2750-6.

   OpenUrlCrossRefPubMed
6. 6.
   1. Cui J,
   2. Saevarsdottir S,
   3. Thomson B, et al.

   Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2010;62:1849-61.

   OpenUrlCrossRefPubMed
7. 7.
   1. Plant D,
   2. Bowes J,
   3. Potter C, et al.

   Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum 2011;63:645-53.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Liu C,
   2. Batliwalla F,
   3. Li W, et al.

   Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol Med 2008;14:575-81.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Wessels JA,
   2. Kooloos WM,
   3. De Jonge R, et al.

   Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2006;54:2830-9.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Lima A,
    2. Bernardes M,
    3. Azevedo R,
    4. Seabra V,
    5. Medeiros R.

    Moving toward personalized medicine in rheumatoid arthritis: SNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome. Pharmacogenomics 2016;17:1649-74.

    OpenUrl
11. 11.↵
    1. Suarez-Gestal M,
    2. Perez-Pampin E,
    3. Calaza M,
    4. Gomez-Reino JJ,
    5. Gonzalez A.

    Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study. Arthritis Res Ther 2010;12:R72.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Plant D,
    2. Prajapati R,
    3. Hyrich KL, et al.

    Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort. Arthritis Rheum 2012;64:665-70.

    OpenUrlCrossRefPubMed